ACC Issues COVID-19 Clinical Guidance for Cardiovascular Care Team
On March 6, 2020, the American College of Cardiology issued COVID-19 clinical guidance for the cardiovascular care team.
On March 6, 2020, the American College of Cardiology issued COVID-19 clinical guidance for the cardiovascular care team.
The treatment of fulminant myocarditis with immunomodulatory therapies adapted to specific subtypes may improve outcomes for patients.
Patients diagnosed with severe myopericarditis were found to also express autoantibodies against RNA polymerase III.
Ethylene glycol toxicity was found to be associated with ST-elevation mimicking myocardial infarction and diffuse repolarization abnormalities.
Acute myocarditis complicated by left ventricular systolic dysfunction confers a higher risk for cardiac death and heart transplant compared with uncomplicated acute myocarditis.
Findings confirm that cardiovascular complications related to commonly-administered, live viral vaccination are rare in adults.